NAD+ / MOTS-c / 5-Amino-1MQ (Mitochondrial Longevity Stack)

Cellular NAD+ is a central currency of mitochondrial metabolism — required for the electron transport chain, sirtuin deacetylase activity (SIRT1, SIRT3), PARP-mediated DNA repair, and CD38-driven calcium signaling. NAD+ levels decline measurably with age in skeletal muscle, liver, and other tissues, and a substantial body of preclinical work has tied that decline to mitochondrial dysfunction, impaired sirtuin signaling, and many of the cellular hallmarks of aging. The longevity peptide community has converged on three complementary interventions that each touch this axis from a different angle. NAD+ precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — are the most clinically advanced of the three. Multiple double-blind RCTs in humans have shown that oral NMN raises blood NAD+ levels in a dose-dependent manner, and a Science RCT (Yoshino et al., 2021) demonstrated improved muscle insulin sensitivity in prediabetic postmenopausal women. The simple framing is: precursors refill the NAD+ pool. The honest framing is: meaningful blood NAD+ elevation has been demonstrated, but downstream functional benefits in healthy adults have been modest and inconsistent across endpoints. MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA. Discovered by Pinchas Cohen's group at USC in 2015, it activates AMPK, promotes glucose disposal, increases muscle insulin sensitivity in mice, and behaves as an exercise-mimetic. It also translocates to the nucleus under metabolic stress to directly regulate adaptive nuclear gene expression — establishing a direct biochemical channel between mitochondrial state and nuclear transcription. MOTS-c plasma levels rise with exercise in humans and decline with age. Human clinical data is thin — primarily observational/biomarker work — but the mechanistic rationale for an exercise-mimetic peptide is among the cleanest in the longevity space. 5-Amino-1MQ (5-amino-1-methylquinolinium iodide, sometimes 5-AMQ) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is the enzyme that methylates nicotinamide to N-methylnicotinamide, consuming both an NAD+ precursor (nicotinamide) and a methyl donor (S-adenosylmethionine, SAM) in the process. NNMT is overexpressed in obese adipose tissue and is mechanistically implicated in metabolic disease via methyl-donor depletion and impaired lipolysis. In diet-induced obesity mouse models, 5-Amino-1MQ produces dramatic reductions in fat mass and body weight, increases in energy expenditure, and changes in white adipose tissue gene expression — pharmacology that maps onto the same metabolic axis as NAD precursors and MOTS-c. Human data is essentially zero; 5-Amino-1MQ is research-chemical territory with no IND-enabling program known publicly. The stack's logic, then: NAD+ precursors supply the substrate, NNMT inhibition prevents the depletion of that substrate (and of methyl donors more broadly), and MOTS-c layers AMPK activation and exercise-mimetic signaling on top. Three intersecting touchpoints on mitochondrial energetics rather than three independent interventions.

The most rigorous synergy is between NAD+ precursors and 5-Amino-1MQ. NNMT consumes nicotinamide (a salvage-pathway NAD+ precursor) and SAM (the universal methyl donor), producing N-methylnicotinamide and S-adenosylhomocysteine. In obesity, NNMT overexpression in adipose tissue drives a net depletion of cellular nicotinamide and SAM, which contributes to metabolic dysfunction through impaired methylation-dependent processes (histone methylation, lipid metabolism, choline biosynthesis). Inhibiting NNMT preserves the nicotinamide pool — which in turn supports NAD+ salvage — and preserves SAM. Layering an NAD+ precursor (NMN or NR) on top supplies additional substrate that is no longer being lost to NNMT-driven methylation. In animal models, this is a clean biochemical synergy. MOTS-c contributes a parallel axis. AMPK activation by MOTS-c shifts cells toward fatty acid oxidation and glucose uptake, mimicking the metabolic signature of exercise. AMPK activation also crosstalks with sirtuin signaling — both are nutrient-status sensors, and they reinforce each other. In skeletal muscle, MOTS-c improves glucose disposal in insulin-resistant mice; in aged mice, restoration of MOTS-c levels improves physical capacity. Whether AMPK activation independent of NAD+ status is sufficient on its own, or whether the combined intervention produces super-additive effects, has not been studied in humans. The sirtuin link is the most-discussed tie between the three components. Sirtuins (especially SIRT1 and SIRT3) are NAD+-dependent deacetylases that respond to cellular energy status — high NAD+ activates them, low NAD+ silences them. Increasing NAD+ pool through precursors and protecting the pool through NNMT inhibition both raise sirtuin substrate availability. AMPK and sirtuins are reciprocally activating in metabolic stress signaling. The hypothetical combined effect is to push the cellular network toward the metabolic state characteristic of caloric restriction and exercise — which is the longevity narrative behind each component individually.

The three components are at very different evidence tiers, and the stack as a stack has zero controlled human evidence. NAD+ precursors (NMN, NR) have the strongest individual evidence base. Multiple Phase 1/2 RCTs in healthy and metabolically compromised adults have shown that oral NMN at 250 mg–1200 mg/day raises blood NAD+ in a dose-dependent fashion, with a generally clean safety profile across 8–12 week trials. Functional endpoints have been mixed — Yoshino et al. (Science 2021) showed improved muscle insulin sensitivity in prediabetic postmenopausal women; Liao et al. demonstrated improved aerobic capacity in amateur runners; Igarashi et al. (GeroScience 2024) reported improvements in walking speed and sleep quality in older adults. Whether these translate to the durable longevity benefits suggested by mouse work remains unsettled. MOTS-c has solid preclinical evidence and limited human translation. Lee et al. (Cell Metabolism 2015) established the metabolic-homeostasis effect in mice; Kim et al. (Cell Metabolism 2018) demonstrated stress-induced nuclear translocation. Human work to date is largely observational — measuring circulating MOTS-c and correlating with exercise, age, and metabolic state. No published Phase 2 RCT has tested exogenous MOTS-c in humans for any indication. Use is research-chemical territory. 5-Amino-1MQ is the most preclinical of the three. Neelakantan et al. (J Med Chem 2018) and follow-up work characterized the medicinal chemistry; rat pharmacokinetic and oral bioavailability studies (Sampson et al., 2021) supported feasibility of oral dosing; in DIO mouse models, NNMT inhibition produces marked reductions in adiposity. Human data is essentially absent, and there is no known IND-enabling pharmaceutical program. Treat 5-Amino-1MQ as a mechanistic probe with translation pending. The combined stack has no clinical trial data. The mechanistic rationale is internally consistent, but inferring effect sizes for a human three-component combination from individual mouse studies and individual NMN RCTs is speculation — not evidence-based protocol design.

There is no clinically validated combined protocol. Doses below reflect what is commonly discussed in longevity and peptide communities, anchored to per-component clinical or preclinical data where available. NAD+ precursors: NMN at 250–600 mg/day orally is the most widely studied range in human RCTs. NR at 300–1000 mg/day is an alternative with similar PK. Some users escalate to higher doses but the clinical evidence above 1200 mg/day is sparse. Single morning dose is typical; some protocols split into morning and afternoon. Sublingual NMN preparations are common but their bioavailability advantage over oral capsules is contested. Injectable NAD+ itself (intravenous or subcutaneous) is a different intervention with its own protocol patterns and is not directly equivalent to oral precursors. MOTS-c: in research-chemical channels, 5–10 mg subcutaneously two to three times per week is the most commonly described pattern, often timed with exercise sessions to align with the natural exercise-induced rise. There is no human dose-finding study, so any specific dose is extrapolation. Cycle lengths of 4–12 weeks with breaks are commonly discussed but have no clinical basis. 5-Amino-1MQ: doses discussed in the community range widely (50–250 mg/day orally), with no human pharmacokinetic basis for any specific number. Animal studies have used much higher doses on a body-weight-corrected basis. Cycle lengths of 4–8 weeks are common. Given the evidence asymmetry, a defensible practical interpretation is: NAD+ precursors as the foundation (clinical evidence exists, safety profile is acceptable), MOTS-c and 5-Amino-1MQ as experimental additions to be approached with appropriate skepticism and clinician oversight rather than as established interventions. The stack is more honest as 'NMN with optional MOTS-c and optional 5-Amino-1MQ' than as a fixed three-component protocol.